An overview of prevalence, determinants and health outcomes of polypharmacy

被引:212
|
作者
Khezrian, Mina [1 ]
McNeil, Chris J. [1 ]
Murray, Alison D. [1 ]
Myint, Phyo K. [2 ]
机构
[1] Univ Aberdeen, Inst Med Sci, Lilian Sutton Bldg,Foresterhill, Aberdeen AB25 2ZD, Scotland
[2] Univ Aberdeen, Inst Appl Hlth Sci, Foresterhill, Aberdeen, Scotland
关键词
health outcome; multimorbidity; older adults; polypharmacy; DWELLING OLDER MEN; ANTICHOLINERGIC BURDEN; CLINICAL CONSEQUENCES; DRUG-USE; FRAILTY; ADULTS; RISK; MORTALITY; CARE; EPIDEMIOLOGY;
D O I
10.1177/2042098620933741
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A high rate of polypharmacy is, in part, a consequence of the increasing proportion of multimorbidity in the ageing population worldwide. Our understanding of the potential harm of taking multiple medications in an older, multi-morbid population, who are likely to be on a polypharmacy regime, is limited. This is a narrative literature review that aims to appraise and summarise recent studies published about polypharmacy. We searched MEDLINE using the search termspolypharmacy(and its variations, e.g. multiple prescriptions, inappropriate drug use, etc.) in titles. Systematic reviews and original studies in English published between 2003 and 2018 were included. In this review, we provide current definitions of polypharmacy. We identify the determinants and prevalence of polypharmacy reported in different studies. Finally, we summarise some of the findings regarding the association between polypharmacy and health outcomes in older adults, with a focus on frailty, hospitalisation and mortality. Polypharmacy was most often defined in terms of the number of medications that are being taken by an individual at any given time. Our review showed that the prevalence of polypharmacy varied between 10% to as high as around 90% in different populations. Chronic conditions, demographics, socioeconomics and self-assessed health factors were independent predictors of polypharmacy. Polypharmacy was reported to be associated with various adverse outcomes after adjusting for health conditions. Optimising care for polypharmacy with valid, reliable measures, relevant to all patients, will improve the health outcomes of older adult population.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Prevalence of polypharmacy in Japan
    Kumamaru, Hiraku
    Matsui, Nobutomo
    Sakuma, Kohta
    Kuan, William Y. H.
    Miyata, Hiroaki
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 538 - 539
  • [22] Prevalence and determinants of polypharmacy in cardiovascular patients attending outpatient clinic in Ethiopia University Hospital
    Tefera, Yonas Getaye
    Alemayehu, Mekuriaw
    Mekonnen, Gashaw Binega
    PLOS ONE, 2020, 15 (06):
  • [23] Moral determinants of health: An overview of disparities in healthcare
    Dissanaike, Sharmila
    Matthews, Jeffrey B.
    JOURNAL OF VASCULAR SURGERY, 2021, 74 (02) : 2S - 5S
  • [24] Prevalence of polypharmacy in Denmark
    Kornholt, Jonatan
    Christensen, Mikkel Bring
    DANISH MEDICAL JOURNAL, 2020, 67 (06):
  • [25] Overview of Social Determinants of Health in the Development of Diabetes
    Hill-Briggs, Felicia
    Fitzpatrick, Stephanie L.
    DIABETES CARE, 2023, 46 (09) : 1590 - 1598
  • [26] The Association of Social Determinants of Health With Health Outcomes
    Krause, Trudy Millard
    Schaefer, Caroline
    Highfield, Linda
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (03): : E89 - +
  • [27] The impact of polypharmacy on health outcomes in the aged: A retrospective cohort study
    Boateng, Irene
    Pascual, Carlos Rodriguez
    Grassby, Paul
    Asghar, Zahid
    Ibrahim, Kinda
    PLOS ONE, 2025, 20 (02):
  • [28] Health care spending as determinants of health outcomes
    Crémieux, PY
    Ouellette, P
    Pilon, C
    HEALTH ECONOMICS, 1999, 8 (07) : 627 - 639
  • [29] Polypharmacy and Associated Health Outcomes in the PARI-HD Study
    Torres-Atencio, Ivonne
    Carreira, Maria B.
    Mendez, Alondra
    Quintero, Maryonelly
    Broce, Adriana
    Oviedo, Diana C.
    Rangel, Giselle
    Villarreal, Alcibiades E.
    Tratner, Adam E.
    Rodriguez-Arana, Sofia
    Britton, Gabrielle B.
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 98 (01) : 287 - 300
  • [30] Polypharmacy in chronic kidney disease: Health outcomes & pharmacy-based strategies to mitigate inappropriate polypharmacy
    Onor, IfeanyiChukwu O.
    Ahmed, Fahamina
    Nguyen, Anthony N.
    Ezebuenyi, Michael C.
    Obi, Collins Uchechukwu
    Schafer, Alison K.
    Borghol, Amne
    Aguilar, Erwin
    Okogbaa, John I.
    Reisin, Efrain
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2024, 367 (01): : 4 - 13